{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:24:21Z","timestamp":1740173061450,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T00:00:00Z","timestamp":1610755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T00:00:00Z","timestamp":1610755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40618-021-01500-z","type":"journal-article","created":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T17:02:20Z","timestamp":1610816540000},"page":"2009-2010","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Primary aldosteronism: considerations about the evaluation of the aldosterone to renin ratio during canrenone treatment"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6433-5155","authenticated-orcid":false,"given":"D.","family":"Armanini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Sabbadin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Boscaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,16]]},"reference":[{"key":"1500_CR1","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1210\/clinem\/dgaa080","volume":"105","author":"GP Rossi","year":"2020","unstructured":"Rossi GP, Ceolotto G, Rossitto G, Maiolino G, Cesari M, Seccia MT (2020) Effects of mineralocorticoid and AT1 receptor antagonism on the aldosterone-renin ratio in primary aldosteronism\u2014the EMIRA study. J Clin Endocrinol Metab 105:2060\u20132067","journal-title":"J Clin Endocrinol Metab"},{"key":"1500_CR2","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr (2016) The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101:1889\u20131916","journal-title":"J Clin Endocrinol Metab"},{"key":"1500_CR3","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1097\/HJH.0000000000002510","volume":"38","author":"P Mulatero","year":"2020","unstructured":"Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro MC, Beuschlein F, Rossi GP, Nishikawa T, Morganti A et al (2020) Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens 38:1919\u20131928","journal-title":"J Hypertens"},{"key":"1500_CR4","first-page":"S157","volume":"3","author":"D Armanini","year":"1985","unstructured":"Armanini D, Strasser T, Weber PC (1985) Binding of agonists and antagonists to mineralocorticoid receptors in human peripheral mononuclear leucocytes. J Hypertens 3:S157-159","journal-title":"J Hypertens"},{"key":"1500_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1365-2265.1985.tb01090.x","volume":"23","author":"Armanini D, Karbowiak I, Goi A, Mantero F, Funder JW","year":"1985","unstructured":"Armanini D, Karbowiak I, Goi A, Mantero F, Funder JW (1985) In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay. Clin Endocrinol 23:341\u2013347","journal-title":"Clin Endocrinol"},{"key":"1500_CR6","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1517\/14656566.2014.896901","volume":"15","author":"D Armanini","year":"2014","unstructured":"Armanini D, Sabbadin C, Don\u00e0 G, Clari G, Bordin L (2014) Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs. Exp Opin Pharmacother 15:909\u2013912","journal-title":"Exp Opin Pharmacother"},{"key":"1500_CR7","unstructured":"Mantero F, Armanini D, Opocher G (1978) Effect of spironolactone and potassium canrenoate on plasma renin activity and plasma and urinary aldosterone in primary aldosteronism. Aldosterone antagonists in clinical medicine. In: Proceedings of the Searle symposium, Nice. Excerpta Medica,vol 103, pp 1629\u20131635"},{"key":"1500_CR8","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/BF03345379","volume":"28","author":"D Armanini","year":"2005","unstructured":"Armanini D, Scaroni C, Mattarello MJ, Fiore C, Albiger N, Sartorato P (2005) Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one-month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate. J Endocrinol Invest 28:236\u2013240","journal-title":"J Endocrinol Invest"},{"key":"1500_CR9","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1161\/HYPERTENSIONAHA.107.088591","volume":"50","author":"D Armanini","year":"2007","unstructured":"Armanini D, Fiore C, Pellati D (2007) Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate. Hypertension 50:e69-70","journal-title":"Hypertension"},{"key":"1500_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1365-2265.2011.04243.x","volume":"76","author":"E Fischer","year":"2012","unstructured":"Fischer E, Beuschlein F, Degenhart C, Endres S, Beuschlein F, Rencke M (2012) Spontaneous remission of idiopathic aldosteronism after long-term treatment with spironolactone: results from the German Conn\u2019s Registry. Clin Endocrinol 76:473\u2013477","journal-title":"Clin Endocrinol"},{"key":"1500_CR11","first-page":"E170","volume":"257","author":"M Wehling","year":"1989","unstructured":"Wehling M, Kuhls S, Armanini D (1989) Volume regulation of human lymphocytes by aldosterone in isotonic media. Am J Physiol 257:E170-174","journal-title":"Am J Physiol"},{"key":"1500_CR12","doi-asserted-by":"publisher","first-page":"E505","DOI":"10.1152\/ajpcell.1987.252.5.C505","volume":"252","author":"M Wehling","year":"1987","unstructured":"Wehling M, Armanini D, Strasser T, Weber PC (1987) Effect of aldosterone on sodium and potassium concentrations in human mononuclear leukocytes. Am J Physiol 252:E505-507","journal-title":"Am J Physiol"},{"key":"1500_CR13","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1210\/jc.2003-031545","volume":"89","author":"L Cal\u00f2","year":"2004","unstructured":"Cal\u00f2 L, Zaghetto F, Pagnin E, Davis PA, De Mozzi P, Sartorato P, Martire G, Fiore C, Armanini D (2004) Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22phox in human mononuclear leukocytes. J Clin Endocrinol Metab 89:1973\u20131976","journal-title":"J Clin Endocrinol Metab"},{"key":"1500_CR14","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1253\/jcj.48.1184","volume":"48","author":"S Ichikawa","year":"1984","unstructured":"Ichikawa S, Tajima Y, Sakamaki T, Matsuo H, Kogure M, Hirano Y, Yagi S, Murata K (1984) Effect of spironolactone on fluid volumes and adrenal steroids in primary aldosteronism. Jpn Circ J 48:1184\u20131196","journal-title":"Jpn Circ J"},{"key":"1500_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1046\/j.1365-2265.2002.01613.x","volume":"57","author":"C Seifarth","year":"2002","unstructured":"Seifarth C, Trenkel S, Schobel H, Hahn E, Hensen H (2002) Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinols 57:457\u2013465","journal-title":"Clin Endocrinols"},{"key":"1500_CR16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709\u2013717","journal-title":"N Engl J Med"},{"key":"1500_CR17","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M (2003) Eplerenone post-acute myocardial infarction heart failure efficacy and Survival Study Investigators. Eplerenone a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309\u20131321","journal-title":"N Engl J Med"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01500-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-021-01500-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01500-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T10:53:49Z","timestamp":1628679229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-021-01500-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,16]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1500"],"URL":"https:\/\/doi.org\/10.1007\/s40618-021-01500-z","relation":{},"ISSN":["1720-8386"],"issn-type":[{"type":"electronic","value":"1720-8386"}],"subject":[],"published":{"date-parts":[[2021,1,16]]},"assertion":[{"value":"24 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}